O E Okosieme1, G Belludi, K Spittle, R Kadiyala, J Richards. 1. Endocrinology and Diabetes Department, Prince Charles Hospital, Cwm Taf Local Health Board, Merthyr Tydfil, Mid Glamorgan, CF47 9DT, UK. okosiemeoe@cf.ac.uk
Abstract
BACKGROUND: Suboptimal thyroid hormone replacement may carry harmful health consequences. AIMS: Our objectives were to determine the prevalence and factors associated with inadequate replacement in patients receiving treatment with levothyroxine. DESIGN: Retrospective general practice audit. METHODS: We identified levothyroxine users through electronic searches of primary care records in all 11 practices within a county borough. The adequacy of thyroid hormone replacement was determined from the current serum, serum thyrotropin (TSH) as: (i) adequate replacement (normal TSH; 0.4-4.0 mU/l); (ii) over replacement (low TSH; <0.4 mU/l); and (iii) under replacement (high TSH; >4.0 mU/l). RESULTS: Out of a registered patient population of 58 567, we identified 1037 patients who were first included in the hypothyroidism disease register between January 2004 and December 2009 (mean age 62.4 ± 15.9 years; female 85.9%, male 14.1%). Inadequate replacement was seen in 385 patients (37.2%), comprising 205 patients (19.8%) with over replacement and 180 patients (17.4%) with under replacement. Step-wise logistic regression showed that the factors associated with under replacement were male gender [odds ratio (OR) 2.85, confidence interval (CI) 1.86-4.38; P < 0.001 and younger age (OR 0.88, CI 0.80-0.98; P = 0.02 per 10 year increase in age) while longer duration of treatment was associated with over-treatment (OR 1.06, CI 1.01-1.10). A thyroid function test was performed in the preceding 12 months in 914 patients (88.1%) and appropriate dose adjustments had been made in 81.0% (312/385) of patients with abnormal results. CONCLUSION: Despite frequent monitoring and dose adjustment activities, inadequate thyroid hormone replacement remained a problem in over a third of levothyroxine users in this population.
BACKGROUND: Suboptimal thyroid hormone replacement may carry harmful health consequences. AIMS: Our objectives were to determine the prevalence and factors associated with inadequate replacement in patients receiving treatment with levothyroxine. DESIGN: Retrospective general practice audit. METHODS: We identified levothyroxine users through electronic searches of primary care records in all 11 practices within a county borough. The adequacy of thyroid hormone replacement was determined from the current serum, serum thyrotropin (TSH) as: (i) adequate replacement (normal TSH; 0.4-4.0 mU/l); (ii) over replacement (low TSH; <0.4 mU/l); and (iii) under replacement (high TSH; >4.0 mU/l). RESULTS: Out of a registered patient population of 58 567, we identified 1037 patients who were first included in the hypothyroidism disease register between January 2004 and December 2009 (mean age 62.4 ± 15.9 years; female 85.9%, male 14.1%). Inadequate replacement was seen in 385 patients (37.2%), comprising 205 patients (19.8%) with over replacement and 180 patients (17.4%) with under replacement. Step-wise logistic regression showed that the factors associated with under replacement were male gender [odds ratio (OR) 2.85, confidence interval (CI) 1.86-4.38; P < 0.001 and younger age (OR 0.88, CI 0.80-0.98; P = 0.02 per 10 year increase in age) while longer duration of treatment was associated with over-treatment (OR 1.06, CI 1.01-1.10). A thyroid function test was performed in the preceding 12 months in 914 patients (88.1%) and appropriate dose adjustments had been made in 81.0% (312/385) of patients with abnormal results. CONCLUSION: Despite frequent monitoring and dose adjustment activities, inadequate thyroid hormone replacement remained a problem in over a third of levothyroxine users in this population.
Authors: Ming Zhang; Jaskanwal D S Sara; Yasushi Matsuzawa; Hossein Gharib; Malcolm R Bell; Rajiv Gulati; Lilach O Lerman; Amir Lerman Journal: Eur Heart J Date: 2016-01-12 Impact factor: 29.983
Authors: Simon H S Pearce; Georg Brabant; Leonidas H Duntas; Fabio Monzani; Robin P Peeters; Salman Razvi; Jean-Louis Wemeau Journal: Eur Thyroid J Date: 2013-11-27
Authors: Marci R Turner; Ximena Camacho; Hadas D Fischer; Peter C Austin; Geoff M Anderson; Paula A Rochon; Lorraine L Lipscombe Journal: BMJ Date: 2011-04-28
Authors: Juan J Díez; Pedro Iglesias; Agustín García; Ángel Mataix; Francisco A Bernabéu-Andréu Journal: Eur Geriatr Med Date: 2021-08-04 Impact factor: 1.710
Authors: Thaer Idrees; Wesley H Prieto; Sabina Casula; Aswathy Ajith; Matthew Ettleson; Flavia A Andreotti Narchi; Pedro S T Russo; Fernando Fernandes; Julie Johnson; Anoop Mayampurath; Rui M B Maciel; Antonio C Bianco Journal: J Endocr Soc Date: 2021-03-06